Navigating the ER+ Breast Cancer Journey: Oral SERDs and the Treatment Landscape

To mark Breast Cancer Awareness Month, we are pleased to share an animated video on treating metastatic breast cancer from Prof. Francois-Clement Bidard.

Explore how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer, as Prof. Bidard explains:

• Why we should determine molecular characteristics for each patient
• When to perform ESR1 mutation testing
• Current treatment guidelines for ER+ metastatic breast cancer

Watch the video and download the accompanying slides below.

Marking Breast Cancer Awareness Month

Clinical Takeaways

• To optimise treatment selection, molecular characterization should be conducted for each patient

• ESR1 mutation testing should preferably be performed using a liquid biopsy platform when recurrence or progression occurs during endocrine therapy

• Elacestrant was the 1st oral SERD to be FDA approved (January 2023), with optimal efficacy and manageable safety for patients with ESR1 mutated ER+/HER2- advanced or metastatic breast cancer

• Oral SERDs are being studied as a monotherapy and in combination with targeted therapies, offering promising prospects for their integration into clinical practice